RESPONSE OF THE BONE AND KIDNEY TO EHDP IN MAN

RESPONSE OF THE BONE AND KIDNEY TO EHDP IN MAN

Detalhes bibliográficos
Main Authors:	Russell, R, Douglas, D, Duckworth, T, Preston, C, Smith, T, Kanis, J, Walton, R, Woods, C, Smith, R
Formato:	Journal article
Publicado em:	1979

Registos relacionados

ABNORMAL RESPONSES TO EHDP TREATMENT OF PAGETS-DISEASE
Por: Smith, R, et al.
Publicado em: (1977)

Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man.
Por: Walton, R, et al.
Publicado em: (1975)

Proceedings: Some effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on calcium metabolism in man.
Por: Walton, R, et al.
Publicado em: (1974)

STUDIES ON HYPERPHOSPHATEMIA INDUCED BY DISODIUM ETHANE-1-HYDROXY-1, 1-DIPHOSPHONATE (EHDP) IN MAN
Por: Walton, R, et al.
Publicado em: (1974)

Effects of a diphosphonate (disodium etidronate: EHDP) on phosphate metabolism in Paget's disease of bone, primary hyperparathyroidism and type I hypophosphataemic rickets.
Por: Walton, R, et al.
Publicado em: (1976)

An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease.
Por: Walton, R, et al.
Publicado em: (1975)

Histological measurements in Paget's disease of bone.
Por: Walton, R, et al.
Publicado em: (1977)

Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
Por: Gray, R, et al.
Publicado em: (1987)

Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
Por: Kanis, J, et al.
Publicado em: (1977)

Biochemical measurements in Paget's disease of bone.
Por: Walton, R, et al.
Publicado em: (1977)

The effect of 1,25-dihydroxycholecalciferol on renal tubular reabsorption of phosphate, intestinal absorption of calcium and bone histology in hypophosphataemic renal tubular rickets.
Por: Russell, R, et al.
Publicado em: (1975)

PLASMA IMMUNOREACTIVE CALCITONIN AND BONE-DISEASE IN DIALYZED PATIENTS
Por: Heynen, G, et al.
Publicado em: (1976)

Effects of 24,25-dihydroxy-vitamin D3 on its plasma level in man.
Por: Kanis, J, et al.
Publicado em: (1981)

Diphosphonates in Paget's disease.
Por: Russell, R, et al.
Publicado em: (1974)

Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
Por: Kanis, J, et al.
Publicado em: (1979)

BIOLOGICAL EFFECTS OF 1,24,25-TRIHYDROXYVITAMIN-D3 IN MAN
Por: Cundy, T, et al.
Publicado em: (1979)

Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
Por: Kanis, J, et al.
Publicado em: (1977)

Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man?
Por: Kanis, J, et al.
Publicado em: (1978)

APPOSITIONAL RATES IN BONE IN PATIENTS WITH CHRONIC RENAL-DISEASE
Por: Earnshaw, M, et al.
Publicado em: (1979)

The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure.
Por: Kanis, J, et al.
Publicado em: (1977)

THERAPEUTIC ADVANTAGE OF 1-ALPHA-HYDROXYLATED COMPOUNDS OVER VITAMIN-D
Por: Kanis, J, et al.
Publicado em: (1977)

Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
Por: Henderson, R, et al.
Publicado em: (1974)

CALCITONIN, BONE-DISEASE, AND CHRONIC RENAL-FAILURE
Por: Cundy, T, et al.
Publicado em: (1978)

Effective short term treatment of Paget's disease with oral etidronate.
Por: Preston, C, et al.
Publicado em: (1986)

Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment.
Por: Smith, R, et al.
Publicado em: (1976)

Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.
Por: Smith, R, et al.
Publicado em: (1973)

Physiological and therapeutic differences between vitamin D, its metabolites and analogues.
Por: Kanis, J, et al.
Publicado em: (1977)

Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
Por: Kanis, J, et al.
Publicado em: (1977)

Proceedings: Some long-term effects of 1,25 dihydroxycholecalciferol (1,25(OH)2D3) in man.
Por: Henderson, R, et al.
Publicado em: (1974)

Physiological and therapeutic differences between vitamin D, its metabolites and analogues
Por: Kanis, J, et al.
Publicado em: (1977)

VITAMIN-DS, MINERALS AND RENAL BONE-DISEASE
Por: Kanis, J, et al.
Publicado em: (1979)

EVIDENCE THAT ENDOGENOUS CALCITONIN PROTECTS AGAINST RENAL BONE-DISEASE
Por: Heynen, G, et al.
Publicado em: (1976)

Everest : the man and the mountain /
Por: Smith, J. R., author
Publicado em: (1999)

1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism.
Por: Russell, R, et al.
Publicado em: (1974)

Challenges for the development of bone-forming agents in Europe
Por: Kanis, J, et al.
Publicado em: (2014)

Challenges for the development of bone-forming agents in Europe.
Por: Kanis, J, et al.
Publicado em: (2014)

Osteomalacia in renal disease.
Por: Kanis, J, et al.
Publicado em: (1980)

‘Man’s inhumanity to man’ and other platitudes of avoidance and misrecognition: an analysis of visitor responses to exhibitions marking the 1807 bicentenary
Por: Laurajane Smith
Publicado em: (2010-11-01)

Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin.
Por: Kanis, J, et al.
Publicado em: (1977)

The vitamin D's in chronic renal failure
Por: Kanis, J, et al.
Publicado em: (1979)